Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Teva Branded Pharmaceutical Products R&D LLC
Age
18–60
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Body mass index (BMI) between 18.5 kg/m2 to 32.0 kg/m2 (inclusive)
Females of childbearing potential agree to take appropriate measures to prevent pregnancy during the study
Males who do not have a documented vasectomy or are not congenitally sterile must agree to abstinence or use of barrier method with spermicide with female partner. Male participant who is having sexual intercourse with a woman of childbearing potential who is not currently pregnant will be advised of her requirement to use an additional highly effective contraceptive method
NOTE - Additional criteria apply, please contact the investigator for more information
You may not be if
Participation in another clinical trial simultaneously
Females who are lactating, breastfeeding, or intends to become pregnant over the course of the study
History of alcohol, drug or any other substance, abuse, addiction or dependence in the last 12 months (except for caffeine)
Major trauma or surgery in the 2 months before screening or at any time between screening and the first dose of IMP, or surgery scheduled during the study or follow-up period
Donated blood or blood products (eg, white blood cells \[WBCs\], platelets, etc.) within the 60 days before screening, or has donated blood or blood products at least twice within the 6 months before screening, or has donated plasma within 7 days of the screening visit or has received blood or blood products in the 6 weeks before screening
Personal or family history of arrhythmia, sudden unexplained death at a young age (before 40 years) in a first-degree relative, or long QT syndrome, or a personal history of syncope, or previous personal treatment for high blood pressure
NOTE - Additional criteria apply, please contact the investigator for more information
Clareo Health | A Study to Assess New Formulations of TEV-56286
